EXHIBIT 10.135



FINAL



FISCAL YEAR 2004 SENIOR EXECUTIVE BONUS PLAN



|(1). | Participants
|---- | ------------



Glenn Cooper (President), Mark Butler (Executive Vice President), Michael Rogers (Executive Vice President), and Bobby Sandage (Executive Vice President).



|(2). | Maximum Available
|---- | -----------------



Base Bonus Pool: Up to 60% of Glenn Coopers base salary; up to 50% of the base salaries of the Executive Vice Presidents (Messrs. Butler, Rogers,
and Sandage)



(Base Salary is defined as the Base Salary at
the time bonuses are paid.)



|(3). | Bonus Pool
|---- | ----------



The amount of Base Bonus Pool received will be calculated based on the following Performance Areas: (a) Business Development; (b) R&D Clinical
Development; (c) Acquisition/In-licensing; (d) Common Stock Performance; and (e) Corporate Finance. The relative weighting of each area has been determined by management and the Compensation Committee, and the total of all areas in Section 4 is
equal to 100% of the Base Bonus Pool.



The allocation of the
pool will be made by the President to the other participants based on participants performance particularly as it relates to his objectives for the year as jointly established with the President. The President may allocate any amount to any
Executive Vice President, including none, but he may not exceed the pool for each individual (50%).



The allocation of the Presidents pool will be made at the discretion of the Board of Directors.



|(4). | Computation of Performance Areas
|---- | --------------------------------



|                                                                                                       |  | Goal |   | Percentage of Total | 
|------------------------------------------------------------------------------------------------------ |  | ---- | - | ------------------- | 
|a.    Business Development                                                                             |  | 25   | %
|-Complete a development/marketing partnership for
Trospium on terms approved by the Board of Directors |  |      |  
|                                                                                                       | 
|b.    R&D/Clinical Development (#1)                                                                    |  | 25   | %
|-Obtain FDA approval to market Trospium in the
United States                                           |  |      |  
|                                                                                                       |  |     



page 1



---

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | Goal |   | Percentage of Total | 
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |  | ---- | - | ------------------- | 
|c.    R&D/Clinical Development (#2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | 10   | %
|-Commence GMP
production of clinical trial material for final QD formulation ofTrospium                                                                                                                                                                                                                                                                                                                                                                                                                            |  |      |  
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 
|d.    R&D/Clinical Development (#3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | 5    | %
|-Commence
multi-dose Phase I trial for IV aminocandin                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |      |  
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 
|e.    Acquisition/In-license                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  | 10   | %
|-Acquire or
in-license a significant new asset (significance to be determined by theCompensation Committee)                                                                                                                                                                                                                                                                                                                                                                                                        |  |      |  
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 
|f.    Common Stock Performance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | 15   | %
|-All or a portion of this goal will be earned based
on the higher of the formulas derivedfrom either the (a) relative stock performance of Indevus Common Stock during thefiscal year or (b) the actual percentage increase in Indevus Common Stock during thefiscal year. Since
achievement of a large increase in Indevus Common Stock either overan Index or over its price at the beginning of the fiscal year is beneficial to theCompanys shareholders, the calculation is made based on the higher
one. |  |      |  



|% of Performance Area |  | IDEV % pts. Increase over initial IDEV price IDEV % pts. above Index
|--------------------- |  | --------------------------------------------------------------------
|25%                   |  | 25%                                                                 
|50%                   |  | 50%                                                                 
|75%                   |  | 75%                                                                 
|100%                  |  | 100%                                                                



|The Index is calculated based on the publicly available
AMEX Biotechnology Index (orclose equivalent if unavailable).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |    
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ---
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 
|In order to capture the return to shareholders during the
fiscal year, the calculation ofthe percentage points increase above Index and the percentage points increase overIDEV stock during the year will be made from the average of two calculations: (1) from10/1/03 to 3/31/04 (six months) and
(2) from 10/1/03 to 9/30/04 (12 months). Due to thepotential for short term news driven fluctuations in stock price, the average of theclosing common stock price for the five trading days up to and including 9/30/03,3/31/04 and 9/30/04
will be used instead of the closing common stock price on that day. |  |    
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 
|g.    Corporate Finance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  | 10%
|-Ensure cash on
hand at end of fiscal year is sufficient to last for at least the following12 months - 50% of goal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |  |    
|-Ensure cash on hand at end of fiscal year is
sufficient to last for at least the following18 months - 100% of goal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |    



page 2



---

|(5). | Additional Goal  Business Development
|---- | --------------------------------------



This additional goal would be over and above any bonuses earned pursuant to Sections 2, 3, 4, 6 and 7. Out-license a second product to a
development/marketing partner on terms approved by the Board of Directors. Achievement of this goal will result in a bonus of 20% of base salary.



|(6). | Additional Goal  Research and Development
|---- | ------------------------------------------



This additional goal would be over and above any bonuses earned pursuant to Sections 2, 3, 4, 5 and 7. Achieve oral bioavailability of aminocandin of 10%
or greater in an appropriate animal model of intestinal absorption. Achievement of this goal will result in a bonus of 20% of base salary.



|(7). | Additional Goal  Strategic Transaction
|---- | ---------------------------------------



This additional goal would be over and above any bonuses earned pursuant to Sections 2, 3, 4, 5 and 6. Complete a transaction, on terms approved by the
Board of Directors, that significantly enhances long-term shareholder value. Achievement of this goal will result in a bonus of 20-60% of base salary, at the discretion of the Compensation Committee.



|(8). | Calculation and Payment
|---- | -----------------------



A recommended calculation of the bonus will be made by management and will be reviewed and approved by the Compensation Committee. Bonuses may be paid
periodically during the fiscal year upon attainment of goals, but not later than October 31, 2004. Payment will be made only to recipients who are still employees of the Company at the time of payment of the bonuses or October 31, 2004, whichever is
earlier.



page 3